Search

Bridgebio Pharma Inc

Open

SectorGezondheidszorg

82.52 0.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

80.75

Max

82.54

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+30.25% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

16B

Vorige openingsprijs

82.51

Vorige sluitingsprijs

82.52

Nieuwssentiment

By Acuity

50%

50%

145 / 340 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jul 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21 jul 2026, 23:51 UTC

News
Social Media

Pegasystems shares declined in after-market trading following second-quarter results that missed analyst expectations for earnings and revenue, amid concerns over future ACV growth.

21 jul 2026, 23:46 UTC

News

Adobe Inc. shares are declining in after-market trading following Morgan Stanley's downgrade to "underweight" and a reduced price target of $240.

21 jul 2026, 23:41 UTC

News

Raytheon Technologies secures a $49.7 million Navy contract for weapon system repairs, with shares trading higher in after-market hours.

21 jul 2026, 23:41 UTC

Social Media
News

Capital One Financial reported adjusted EPS of $5.81 and revenue of $15.85 billion, exceeding expectations, as shares rose in after-market trading.

21 jul 2026, 23:41 UTC

Macro News
ETF Constituents
News

Vanguard Information Technology ETF is little changed after market hours, despite broader market gains and negative contributions from Apple, Microsoft, and Nvidia.

21 jul 2026, 23:36 UTC

News
ETF Constituents

The Vanguard Growth ETF is trading roughly flat in after-market hours, reflecting minor fluctuations among its holdings, including declines from Apple, Microsoft, and Nvidia.

21 jul 2026, 23:36 UTC

Social Media
News

Micron Technology rose in after-market hours, supported by a semiconductor rally and a Bank of America upgrade to "buy" on strong AI demand.

21 jul 2026, 23:36 UTC

News

MongoDB shares traded higher after director Dwight Merriman sold 16,000 shares for $5.2 million under a pre-scheduled plan, retaining $496.55 million in holdings.

21 jul 2026, 23:32 UTC

News

United Community Banks Inc. shares rise in after-market trading after an upgrade to Buy, bolstered by Q2 2026 net interest income of $270.7 million.

21 jul 2026, 23:26 UTC

Correlated Moves
News

JPMorgan Chase & Co shares showed little change in after-market hours amid broader market movements. CEO Jamie Dimon raised concerns over geopolitical tensions and inflation.

21 jul 2026, 23:26 UTC

Social Media
Correlated Moves
News

Coinbase Global shares rose in after-market trading amid reports of a regulatory agreement that may benefit digital assets, with Bitcoin approaching $67,000.

21 jul 2026, 23:26 UTC

News

Lucid Group Inc. faces a class action lawsuit over alleged supplier quality issues, contributing to a decline in after-market trading. Shares earlier stabilized after a session low.

21 jul 2026, 23:26 UTC

News

Intuit Inc. shares are lower in after-market trading following a class action lawsuit alleging misleading statements about TurboTax revenue growth and competitive advantages.

21 jul 2026, 23:16 UTC

News

Sprinklr Inc reported first-quarter revenues of $219.5 million, exceeding expectations, but shares are lower in after-market hours amid sector concerns and mixed AI sentiments.

21 jul 2026, 23:16 UTC

News

Nasdaq shares rise in after-market hours following the dismissal of all claims in the Miami International litigation, positively impacting investor sentiment.

21 jul 2026, 23:16 UTC

News

Iridium Communications Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid significant gains in technology and semiconductor stocks in Asia.

21 jul 2026, 23:16 UTC

News

Intel faces valuation scrutiny as modest growth expectations contrast with sector leaders benefiting from AI demand. Shares were roughly flat in after-market hours.

21 jul 2026, 23:11 UTC

News

Toast Inc shares are trading higher in after-market hours following the announcement of its second quarter 2026 financial results release on August 4.

21 jul 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

21 jul 2026, 23:06 UTC

News

General Motors plans a new generation of gasoline-powered Cadillac models, shifting from an all-electric strategy. Shares are higher in after-market trading.

21 jul 2026, 23:02 UTC

News

Park Aerospace shares lower in after-market hours following the unexpected death of Vice President Daniel McNamara, impacting investor sentiment and contributing to the decline.

21 jul 2026, 23:02 UTC

Event
News

Weatherford International shares advanced in after-market trading following second-quarter results, with revenues of $1.11 billion exceeding expectations despite a decline.

21 jul 2026, 23:02 UTC

News

Jefferies raised its price target on Genuine Parts Co to $130.00, contributing to after-market gains following a dip earlier in the session.

21 jul 2026, 23:02 UTC

Event
News
Social Media

AAR Corp shares are lower in after-market trading following mixed fourth-quarter results and cautious guidance, despite exceeding sales and EPS expectations.

21 jul 2026, 23:02 UTC

News

ServiceNow Inc. shares declined in after-market hours amid concerns about generative AI's impact on the enterprise software sector, according to Morgan Stanley.

21 jul 2026, 23:01 UTC

News
Social Media

Citigroup Inc declared a quarterly dividend of $0.67 per share, though shares are trading lower after-market amid ongoing market weakness.

21 jul 2026, 23:01 UTC

News

Norfolk Southern announced a quarterly dividend of $1.35 per share, contributing to shares trading higher in after-market hours following three lower sessions.

21 jul 2026, 23:01 UTC

News

DigitalOcean shares rise in after-market hours after Baird analyst initiates coverage with an Outperform rating. The stock closed at $119.09 in the prior session.

21 jul 2026, 23:01 UTC

News
Social Media

Chubb Ltd reported second-quarter net income of $2.85 billion, down from $2.97 billion a year earlier, contributing to lower after-market trading.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

30.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.39 USD  30.25%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

145 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat